Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CCR3 | P51677 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13931081 | 0.92 | OPRM1 (0.44) | SMN1; SMN2MAPTTP53OPRM1ALDH1A1 | |
| SCHEMBL13930712 | 0.87 | SMN1; SMN2 (0.49) | SMN1; SMN2POLBNPC1RAB9AMAPT | |
| SCHEMBL13952140 | 0.83 | TPSAB1 (0.50) | MAPTOPRM1EPHX2MEN1KMT2A | |
| SCHEMBL13930654 | 0.82 | CA1 (0.49) | MAPTOPRM1MEN1KMT2ACCR3 | |
| SCHEMBL13930716 | 0.81 | UBE2M (0.46) | SMN1; SMN2POLBNPC1RAB9AMAPT | |
| SCHEMBL13952139 | 0.80 | RORC (0.55) | MAPTMEN1KMT2ACCR3 | |
| SCHEMBL13930692 | 0.79 | UBE2M (0.49) | SMN1; SMN2POLBRAB9AMAPTOPRM1 | |
| SCHEMBL13930609 | 0.79 | EPHX2 (0.57) | SMN1; SMN2MAPTTP53OPRM1ALDH1A1 | |
| SCHEMBL13930715 | 0.79 | UBE2M (0.46) | SMN1; SMN2MAPTTP53OPRM1ALDH1A1 | |
| SCHEMBL13930704 | 0.79 | TPSAB1 (0.46) | SMN1; SMN2POLBNPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | EUROSCREEN S.A. (BE) | 2009-02-19 | — | — | US | disclosed |
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | EUROSCREEN S.A. (BE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | ALDH1A1, ABAT, ALDH18A1 | SMN1; SMN2 2750/4885POLB 1789/4885NPC1 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.